menu

Expert Insights on Current and Future Therapies in IgAN & FSGS: Patient Case Review

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Achieving Success in IgAN & FSGS

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Can you do better than the experts in treating immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)? Using a case-based vignette, chairperson Siân Griffin, MD, PhD, and faculty members Jürgen Floege, MD, and Loreto Gesualdo, MD, will provide expert analysis regarding the value of lowering proteinuria and offer insights on applying clinical trial data to the unique challenges of managing advanced nephropathy. Learn how novel mechanisms, innovative treatments, and emerging data are leading to successful outcomes in patients with IgAN and FSGS.   

    To view the full symposium on Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies, click here

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Siân Griffin, MD, PhD
    Consultant Nephrologist
    Honorary Professor, Cardiff University
    Department of Nephrology and Transplantation
    University Hospital of Wales
    Cardiff, United Kingdom

    Consulting Fees: Alexion Pharma UK Ltd., Bayer, Eledon, Takeda, Travere

    Faculty:
    Jürgen Floege, MD
    Director
    RWTH Aachen University Hospital
    Aachen, Germany

    Consulting Fees: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
    Other: Novo Nordisk, Visterra

    Loreto Gesualdo, MD, FERA
    Full Professor of Nephrology
    University of Bari Aldo Moro
    Bari, Italy

    Research grants: Abionyx, Sanofi
    Speaking and Consulting Fees: Astellas, AstraZeneca, Baxter, Chinook, Estor, Fresenius, GSK, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, Travere, Werfen 
    Other: PersonGene, MedPath

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Diagnose immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
    • Discuss current treatment considerations in IgAN and FSGS
    • Utilize recent clinical trial data in the formulation of treatment plans to achieve sustained proteinuria remission in patients with IgAN 
  • Target Audience

    This activity is designed to meet the educational needs of nephrology healthcare professionals.

  • Accreditation and Credit Designation Statements

     In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™  to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this enduring activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 8/14/2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a link outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Can you do better than the experts in treating immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)? Using a case-based vignette, chairperson Siân Griffin, MD, PhD, and faculty members Jürgen Floege, MD, and Loreto Gesualdo, MD, will provide expert analysis regarding the value of lowering proteinuria and offer insights on applying clinical trial data to the unique challenges of managing advanced nephropathy. Learn how novel mechanisms, innovative treatments, and emerging data are leading to successful outcomes in patients with IgAN and FSGS.   

    To view the full symposium on Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies, click here

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Siân Griffin, MD, PhD
    Consultant Nephrologist
    Honorary Professor, Cardiff University
    Department of Nephrology and Transplantation
    University Hospital of Wales
    Cardiff, United Kingdom

    Consulting Fees: Alexion Pharma UK Ltd., Bayer, Eledon, Takeda, Travere

    Faculty:
    Jürgen Floege, MD
    Director
    RWTH Aachen University Hospital
    Aachen, Germany

    Consulting Fees: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
    Other: Novo Nordisk, Visterra

    Loreto Gesualdo, MD, FERA
    Full Professor of Nephrology
    University of Bari Aldo Moro
    Bari, Italy

    Research grants: Abionyx, Sanofi
    Speaking and Consulting Fees: Astellas, AstraZeneca, Baxter, Chinook, Estor, Fresenius, GSK, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, Travere, Werfen 
    Other: PersonGene, MedPath

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Diagnose immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
    • Discuss current treatment considerations in IgAN and FSGS
    • Utilize recent clinical trial data in the formulation of treatment plans to achieve sustained proteinuria remission in patients with IgAN 
  • Target Audience

    This activity is designed to meet the educational needs of nephrology healthcare professionals.

  • Accreditation and Credit Designation Statements

     In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™  to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this enduring activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 8/14/2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a link outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule27 May 2024